Clearmind Medicine (CMND) Delivers Positive AUD Trial Data Amid New Depression Patent – Nov. 18, 2025
Clearmind Medicine reported positive safety results from the first cohort of its FDA-approved Phase I/IIa trial of CMND-100 for alcohol use disorder. No serious adverse events were observed among six participants treated at Johns Hopkins and Yale. CMND shares surged to $0.39 intraday on heavy volume before settling near $0.27 by mid-afternoon November 18. The company also announced a new Israeli patent filing and an expected equity offering.
